Special Issue "Cholinesterase Inhibitors"
Deadline for manuscript submissions: 31 August 2019
Acetylcholinesterase (AChE, EC 22.214.171.124) plays a pivotal role in cholinergic transmission in the central nervous system and at the neuromuscular junctions (NMJ). Even if its physiological role has not yet been identified, butyrylcholinesterase (BChE, EC 126.96.36.199), also named pseudocholinesterase, is well known to play a role in metabolizing bioactive esters (e.g., succinylcholine, cocaine). The effects of cholinesterase inhibitors (ChEIs) have been investigated in diseases associated with a cholinergic deficit, such as Alzheimer's disease (AD) and other dementias. Although ChEIs afford mostly a symptomatic response to AD patients, the development of new ChEIs (e.g., multifunctional ligands, selective BChE inhibitors) remains of interest to treat neurodegenerative diseases. ChEIs may also be used as a treatment for an autoimmune disease named Myastenia Gravis, by targeting nicotinic acetylcholine receptors at the NMJ, and as a prophylactic treatment against organophosphorus nerve agents poisoning. On the basis of their mechanism of action, ChEIs are classified into three groups: reversible (e.g., tacrine); pseudoirreversible (e.g., rivastigmine), and irreversible (e.g., echothiophate).
In this Special Issue, we invite you to submit original research papers or reviews, which report on the design, synthesis, and biological evaluation of novel ChEIs.
Dr. Ludovic Jean
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Myasthenia Gravis
- Organophosphorus compounds
- Drug discovery
- Rational design